Kintegral Advisory LLC Lowers Position in Edwards Lifesciences Co. (NYSE:EW)

Kintegral Advisory LLC decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 68,776 shares of the medical research company’s stock after selling 3,204 shares during the period. Kintegral Advisory LLC’s holdings in Edwards Lifesciences were worth $5,091,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences during the third quarter valued at approximately $32,000. Avior Wealth Management LLC grew its stake in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares in the last quarter. Finally, JFS Wealth Advisors LLC increased its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,555,402. This trade represents a 12.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,489 shares of company stock valued at $2,002,829 over the last three months. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

EW opened at $73.25 on Friday. The stock’s 50 day moving average price is $72.85 and its 200-day moving average price is $69.94. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market capitalization of $43.20 billion, a PE ratio of 10.51, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

EW has been the subject of several research reports. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Morgan Stanley upped their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Truist Financial reissued a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Finally, Robert W. Baird lowered their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.